American Journal of Cardiology
Volume 104, Issue 1 , Pages 36-40, 1 July 2009

Timing and Duration of Myocardial Ischemia on Holter Monitoring Following Percutaneous Coronary Intervention and Their Association With Clinical Outcomes (a PROTECT-TIMI 30 Substudy Analysis)

  • C. Michael Gibson, MS, MD

      Affiliations

    • TIMI Study Group, Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
    • Corresponding Author InformationCorresponding author: Tel: 617-525-6884; fax: 888-249-5261
  • ,
  • Yuri B. Pride, MD

      Affiliations

    • Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
  • ,
  • Jacqueline L. Buros, BS

      Affiliations

    • TIMI Study Group, Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
  • ,
  • Lauren N. Ciaglo, BA

      Affiliations

    • TIMI Study Group, Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
  • ,
  • David A. Morrow, MD

      Affiliations

    • TIMI Study Group, Brigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts
  • ,
  • Benjamin M. Scirica, MD

      Affiliations

    • TIMI Study Group, Brigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts
  • ,
  • Peter H. Stone, MD

      Affiliations

    • Division of Cardiovascular Medicine, Department of Medicine, Brigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts
  • ,
  • TIMI Study Group

Received 31 December 2008; received in revised form 20 February 2009; accepted 20 February 2009. published online 04 May 2009.

In patients with unstable angina, evidence of myocardial ischemia on Holter monitoring is associated with an adverse prognosis. However, the association of duration and timing of ischemia on Holter monitoring with outcomes after percutaneous coronary intervention (PCI) in patients with non–ST-segment elevation acute coronary syndromes (NSTEACSs) has not been systematically evaluated. PROTECT-TIMI 30 randomized 857 patients with NSTEACSs undergoing PCI to eptifibatide plus a heparin product or bivalirudin monotherapy. Patients underwent continuous Holter monitoring following PCI, and the association between ischemia and clinical outcomes was evaluated retrospectively. Forty-three patients (5.0%) had ischemia on Holter after PCI. Any ischemia was associated with a significant increase in the incidence of death or myocardial infarction (MI) within 48 hours (32.6% vs 6.1%, odds ratio 7.5, 95% confidence interval 3.70 to 15.10, p <0.001). In patients who developed ischemia, there was a 1.44-fold increase in the odds for death or MI for every 30 minutes of ischemia (95% confidence interval 1.12 to 1.84, p = 0.004). Duration of ischemic events was related to their timing, such that ischemic events that occurred within the first 4 hours after PCI (median duration 141 minutes, interquartile range 36 to 227.5) were significantly longer than events occurring 4 to 24 hours after PCI (median duration 32.8 minutes, interquartile range 17.5 to 118, p = 0.041). In conclusion, early ischemia after PCI for NSTEACS is of longer duration, and longer duration of ischemia recognized by Holter monitoring is associated with an increased incidence of death or MI. Holter monitoring may be a useful surrogate end point in clinical trials.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 This word was supported in part by grants from Millennium Pharmaceuticals, Cambridge, Massachusetts, and Schering-Plough Research Institute, Kennilworth, New Jersey.

PII: S0002-9149(09)00664-X

doi:10.1016/j.amjcard.2009.02.044

American Journal of Cardiology
Volume 104, Issue 1 , Pages 36-40, 1 July 2009